|
1
|
Wu Y, Nasifu L, He B. Author reply to Wang et al.: "The Diagnostic and Prognostic Value of miR-155 in Cancers: An Updated Meta‑analysis". Mol Diagn Ther 2024; 28:509-511. [PMID: 38780685 DOI: 10.1007/s40291-024-00711-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/14/2024] [Indexed: 05/25/2024]
Affiliation(s)
- Yanan Wu
- Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China
- Department of Laboratory Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China
| | - Lubanga Nasifu
- Department of Laboratory Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China
- Department of Biology, Muni University, Arua, Uganda
| | - Bangshun He
- Department of Laboratory Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
- Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China.
| |
Collapse
|
|
2
|
Laborda-Illanes A, Aranega-Martín L, Sánchez-Alcoholado L, Boutriq S, Plaza-Andrades I, Peralta-Linero J, Garrido Ruiz G, Pajares-Hachero B, Álvarez M, Alba E, González-González A, Queipo-Ortuño MI. Exploring the Relationship between MicroRNAs, Intratumoral Microbiota, and Breast Cancer Progression in Patients with and without Metastasis. Int J Mol Sci 2024; 25:7091. [PMID: 39000198 PMCID: PMC11241717 DOI: 10.3390/ijms25137091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2024] [Revised: 06/07/2024] [Accepted: 06/24/2024] [Indexed: 07/16/2024] Open
Abstract
Breast cancer (BC) continues to pose a significant burden on global cancer-related morbidity and mortality, primarily driven by metastasis. However, the combined influence of microRNAs (miRNAs) and intratumoral microbiota on BC metastasis remains largely unexplored. In this study, we aimed to elucidate the interplay between intratumoral microbiota composition, miRNA expression profiles, and their collective influence on metastasis development in BC patients by employing 16S rRNA sequencing and qPCR methodologies. Our findings revealed an increase in the expression of miR-149-5p, miR-20b-5p, and miR-342-5p in metastatic breast cancer (Met-BC) patients. The Met-BC patients exhibited heightened microbial richness and diversity, primarily attributed to diverse pathogenic bacteria. Taxonomic analysis identified several pathogenic and pro-inflammatory species enriched in Met-BC, contrasting with non-metastatic breast cancer (NonMet-BC) patients, which displayed an enrichment in potential probiotic and anti-inflammatory species. Notably, we identified and verified a baseline prognostic signature for metastasis in BC patients, with its clinical relevance further validated by its impact on overall survival. In conclusion, the observed disparities in miRNA expression and species-level bacterial abundance suggest their involvement in BC progression. The development of a prognostic signature holds promise for metastasis risk assessment, paving the way for personalized interventions and improved clinical outcomes in BC patients.
Collapse
Affiliation(s)
- Aurora Laborda-Illanes
- Clinical Management Unit of Medical Oncology, Regional and Virgen de la Victoria University Hospitals-IBIMA BIONAND-CIMES-UMA Platform, 29010 Málaga, Spain; (A.L.-I.); (L.A.-M.); (L.S.-A.); (S.B.); (I.P.-A.); (J.P.-L.); (B.P.-H.); (M.Á.); (E.A.)
- Faculty of Medicine, University of Málaga, Andalucía Tech, Campus de Teatinos s/n, 29071 Málaga, Spain
| | - Lucía Aranega-Martín
- Clinical Management Unit of Medical Oncology, Regional and Virgen de la Victoria University Hospitals-IBIMA BIONAND-CIMES-UMA Platform, 29010 Málaga, Spain; (A.L.-I.); (L.A.-M.); (L.S.-A.); (S.B.); (I.P.-A.); (J.P.-L.); (B.P.-H.); (M.Á.); (E.A.)
- Faculty of Medicine, University of Málaga, Andalucía Tech, Campus de Teatinos s/n, 29071 Málaga, Spain
| | - Lidia Sánchez-Alcoholado
- Clinical Management Unit of Medical Oncology, Regional and Virgen de la Victoria University Hospitals-IBIMA BIONAND-CIMES-UMA Platform, 29010 Málaga, Spain; (A.L.-I.); (L.A.-M.); (L.S.-A.); (S.B.); (I.P.-A.); (J.P.-L.); (B.P.-H.); (M.Á.); (E.A.)
- Faculty of Medicine, University of Málaga, Andalucía Tech, Campus de Teatinos s/n, 29071 Málaga, Spain
| | - Soukaina Boutriq
- Clinical Management Unit of Medical Oncology, Regional and Virgen de la Victoria University Hospitals-IBIMA BIONAND-CIMES-UMA Platform, 29010 Málaga, Spain; (A.L.-I.); (L.A.-M.); (L.S.-A.); (S.B.); (I.P.-A.); (J.P.-L.); (B.P.-H.); (M.Á.); (E.A.)
| | - Isaac Plaza-Andrades
- Clinical Management Unit of Medical Oncology, Regional and Virgen de la Victoria University Hospitals-IBIMA BIONAND-CIMES-UMA Platform, 29010 Málaga, Spain; (A.L.-I.); (L.A.-M.); (L.S.-A.); (S.B.); (I.P.-A.); (J.P.-L.); (B.P.-H.); (M.Á.); (E.A.)
| | - Jesús Peralta-Linero
- Clinical Management Unit of Medical Oncology, Regional and Virgen de la Victoria University Hospitals-IBIMA BIONAND-CIMES-UMA Platform, 29010 Málaga, Spain; (A.L.-I.); (L.A.-M.); (L.S.-A.); (S.B.); (I.P.-A.); (J.P.-L.); (B.P.-H.); (M.Á.); (E.A.)
| | | | - Bella Pajares-Hachero
- Clinical Management Unit of Medical Oncology, Regional and Virgen de la Victoria University Hospitals-IBIMA BIONAND-CIMES-UMA Platform, 29010 Málaga, Spain; (A.L.-I.); (L.A.-M.); (L.S.-A.); (S.B.); (I.P.-A.); (J.P.-L.); (B.P.-H.); (M.Á.); (E.A.)
| | - Martina Álvarez
- Clinical Management Unit of Medical Oncology, Regional and Virgen de la Victoria University Hospitals-IBIMA BIONAND-CIMES-UMA Platform, 29010 Málaga, Spain; (A.L.-I.); (L.A.-M.); (L.S.-A.); (S.B.); (I.P.-A.); (J.P.-L.); (B.P.-H.); (M.Á.); (E.A.)
- Department of Human Physiology, Human Histology, Pathological Anatomy and Physical Education, Faculty of Medicine, University of Málaga, 29071 Málaga, Spain
| | - Emilio Alba
- Clinical Management Unit of Medical Oncology, Regional and Virgen de la Victoria University Hospitals-IBIMA BIONAND-CIMES-UMA Platform, 29010 Málaga, Spain; (A.L.-I.); (L.A.-M.); (L.S.-A.); (S.B.); (I.P.-A.); (J.P.-L.); (B.P.-H.); (M.Á.); (E.A.)
- Department of Medicine, Faculty of Medicine, University of Málaga, 29071 Málaga, Spain
| | - Alicia González-González
- Clinical Management Unit of Medical Oncology, Regional and Virgen de la Victoria University Hospitals-IBIMA BIONAND-CIMES-UMA Platform, 29010 Málaga, Spain; (A.L.-I.); (L.A.-M.); (L.S.-A.); (S.B.); (I.P.-A.); (J.P.-L.); (B.P.-H.); (M.Á.); (E.A.)
- UGC Endocrinology and Nutrition, Regional University Hospital of Málaga, Institute of Biomedical Research of Málaga (IBIMA), Faculty of Medicine, University of Málaga, 29071 Málaga, Spain
| | - María Isabel Queipo-Ortuño
- Clinical Management Unit of Medical Oncology, Regional and Virgen de la Victoria University Hospitals-IBIMA BIONAND-CIMES-UMA Platform, 29010 Málaga, Spain; (A.L.-I.); (L.A.-M.); (L.S.-A.); (S.B.); (I.P.-A.); (J.P.-L.); (B.P.-H.); (M.Á.); (E.A.)
- Department of Surgical Specialties, Biochemistry and Immunology, Faculty of Medicine, University of Málaga, 29071 Málaga, Spain
| |
Collapse
|
|
3
|
Wang F, Wang J, Zhang H, Fu B, Zhang Y, Jia Q, Wang Y. Diagnostic value of circulating miR-155 for breast cancer: a meta-analysis. Front Oncol 2024; 14:1374674. [PMID: 38590648 PMCID: PMC10999615 DOI: 10.3389/fonc.2024.1374674] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2024] [Accepted: 03/07/2024] [Indexed: 04/10/2024] Open
Abstract
Backgrounds The value of circulating microRNA (miR)-155 for breast cancer (BC) diagnosis may differ in different studies. Therefore, we conducted this systematic review and meta-analysis to evaluate the potential application of circulating miR-155 in the diagnosis of BC. Methods Articles published before December 2023 and in English were searched in these databases: PubMed, Web of Science, Medline, EMBASE and Google Scholar. A summary of sensitivity, specificity, positive likelihood ratios (PLR), negative likelihood ratios (NLR), and diagnostic odds ratio (DOR) were calculated from the true positive (TP), true negative (TN), false positive (FP) and false negative (FN) of each study. Additionally, the summary receive-operating characteristics (SROC) curve was constructed to summarize the TP and FP rates. Results The pooled parameters calculated were as follows: sensitivity, 0.93 (95% CI: 0.83-0.97); specificity, 0.85 (95% CI: 0.74-0.92); PLR, 6.4 (95% CI: 3.4-11.9); NLR, 0.09 (95% CI: 0.04-0.20); and DOR, 74 (95% CI: 22-247). The analysis showed a significant heterogeneity (sensitivity, I2 = 95.19%, p < 0.001; specificity, I2 = 95.29%, p < 0.001; DOR, I2 = 92.9%, p < 0.001). The SROC curve was with an area under curve (AUC) of 0.95 (95% CI: 0.93-0.97). Conclusion Circulating miR-155 has a potential in the diagnosis of BC.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Yong Wang
- Department of Oncology, Anhui University of Technology First Affiliated Hospital Huainan, Huainan, Anhui, China
| |
Collapse
|
|
4
|
Wu Y, Hong Q, Lu F, Zhang Z, Li J, Nie Z, He B. The Diagnostic and Prognostic Value of miR-155 in Cancers: An Updated Meta-analysis. Mol Diagn Ther 2023; 27:283-301. [PMID: 36939982 DOI: 10.1007/s40291-023-00641-6] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/07/2023] [Indexed: 03/21/2023]
Abstract
BACKGROUND MicroRNA-155 has been discussed as a biomarker in cancer diagnosis and prognosis. Although relevant studies have been published, the role of microRNA-155 remains uncertain because of insufficient data. METHODS We conducted a literature search in PubMed, Embase, and Web of Science databases to obtain relevant articles and extract data to evaluate the role of microRNA-155 in cancer diagnosis and prognosis. RESULTS The pooled results showed that microRNA-155 presented a remarkable diagnostic value in cancers (area under the curve = 0.90, 95% confidence interval (CI 0.87-0.92; sensitivity = 0.83, 95% CI 0.79-0.87; specificity = 0.83, 95% CI 0.80-0.86), which was maintained in the subgroups stratified by ethnicity (Asian and Caucasian), cancer types (breast cancer, lung cancer, hepatocellular carcinoma, leukemia, and pancreatic ductal adenocarcinoma), sample types (plasma, serum, tissue), and sample size (n >100 and n <100). In prognosis, a combined hazard ratio (HR) showed that microRNA-155 was significantly associated with poor overall survival (HR = 1.38, 95% CI 1.25-1.54) and recurrence-free survival (HR = 2.13, 95% CI 1.65-2.76), and was boundary significant with poor progression-free survival (HR = 1.20, 95% CI 1.00-1.44), but not significant with disease-free survival (HR = 1.14, 95% CI 0.70-1.85). Subgroup analyses in overall survival showed that microRNA-155 was associated with poor overall survival in the subgroups stratified by ethnicity and sample size. However, the significant association was maintained in cancer types subgroups of leukemia, lung cancer, and oral squamous cell carcinoma, but not in colorectal cancer, hepatocellular carcinoma, and breast cancer, and was maintained in sample types subgroups of bone marrow and tissue, but not in plasma and serum. CONCLUSIONS Results from this meta-analysis demonstrated that microRNA-155 was a valuable biomarker in cancer diagnosis and prognosis.
Collapse
Affiliation(s)
- Yanan Wu
- Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China
- Department of Laboratory Medicine, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Qinhuai District, Nanjing, Jiangsu, China
| | - Qiwei Hong
- Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China
- Department of Laboratory Medicine, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Qinhuai District, Nanjing, Jiangsu, China
| | - Fang Lu
- Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China
- Department of Laboratory Medicine, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Qinhuai District, Nanjing, Jiangsu, China
| | - Zhongqiu Zhang
- Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Jingjing Li
- Department of Laboratory Medicine, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Qinhuai District, Nanjing, Jiangsu, China
| | - Zhenlin Nie
- Department of Laboratory Medicine, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Qinhuai District, Nanjing, Jiangsu, China.
| | - Bangshun He
- Department of Laboratory Medicine, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Qinhuai District, Nanjing, Jiangsu, China.
- Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China.
| |
Collapse
|